Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TFF3

TFF3

Basics

Aliases:
This biomarker is also known as:
  • Trefoil Factor 3 (Intestinal),
  • P1B,
  • Intestinal Trefoil Factor,
  • TFI,
  • Trefoil Factor 3,
  • HP1.B,
  • ITF,
  • Polypeptide P1.B,
  • Trefoil Factor 3, HITF, Human Intestinal Trefoil Factor11,
  • HITF,

View in BioMuta

Description…

TFF3 is a member of the trefoil factor family. The trefoil factors are secreted peptides produced by normal intestinal mucosa, characterized by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulfides.

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: TFF3

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Two
QA State: Curated

Overview

Through gene expression profiling studies TFF3 mRNA has been found to be overexpressed in prostate cancer.

Performance Comment

Increased TFF3 transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.